STOCKS TELEGRAPH

Tag: TLSA

  • Positive Clinical Results: Tiziana Life Sciences PLC (TLSA) Stock Rising in Early Trading.

    Positive Clinical Results: Tiziana Life Sciences PLC (TLSA) Stock Rising in Early Trading.

    Tiziana Life Sciences PLC (TLSA) is a late-stage biotherapeutics enterprise focused on the development of groundbreaking therapeutics. The company’s nasal, and oral therapies have an edge over intravenous delivery. Two lead product candidates of the company include intranasal foralumab and milciclib.

    The price of TLSA stock during the early trading of March 10, 2022, was last checked to be $0.96 with a vertical gain of 25.27%.

    TLSA: Events and Happenings

    On March 10, 2022, TLSA reported optimistic clinical results in the treatment of Secondary Progressive Multiple Sclerosis, following the conclusion of six months of dosage with foralumab. Biological and clinical developments were observed in the patient along with good tolerability using the company’s innovative immunotherapeutics.

    On March 01, 2022, TLSA updated on its publication of data of the highly prognostic potential of StemPrintER for risk of distant reappearance in breast cancer patients in the European Journal of Cancer. On February 10, 2022, TLSA announced its Executive management’s participation at the Virtual BIO CEO & Investor Conference 2022 held on February 14-15, 2022.

    On February 04, 2022, TLSA informed the press about the modified submission of IND application of foralumab to the FDA for its assessment in patients with Crohn’s Disease.

    TLSA: Key Financials

    On September 24, 2021, TLSA reported its interim financial statement for the first half of 2021 ended June 30, 2021. Some of the key aspects are as follows.

    EPS

    Basic and diluted loss attributed to the equity owners per share in H1 2021 was reported to be £12.5 million or 7.4 pence comparable to £3.91 million or 2.6 pence in the same half of 2020. The company noted a considerable gain in its loss over the year.

    Conclusion

    TLSA stock dropped by 82% from the past year as the pandemic laid the financial conditions down globally. Recently, in the early trading, the company’s stock showed signs of improvement as it proclaimed positive clinical outcomes for foralumab.

  • Tiziana Life Sciences Inc. (TLSA) stock rises in the current market trading. Why is it so?

    Tiziana Life Sciences Inc. (TLSA) stock surges by 9.06% in the current market trading session after TLSA stock announced the positive progress of the Foralumab program, which is designed to counter COVID-19 and secondary progressive multiple sclerosis. Tiziana Life Sciences plc is a dual-listed biotechnology firm specializing in the research and development of novel molecules to fight diseases like cancer, inflammation, and other infectious diseases in humans.

    What is happening?

    TLSA stock has declared that the US Food and Drug Administration (FDA) has approved the use of Foralumab, a completely human anti-CD3 monoclonal antibody, in a secondary progressive multiple sclerosis (SPMS) patient at Harvard University’s Brigham and Women’s Hospital (BWH), Boston, MA. This is the first time a nasally administered antibody will be provided to a patient with SPMS, and it will be handled under an Individual Patient Expanded Access IND. The treatment will begin in the second quarter of 2021 and will last for six months.

    To test microglial imaging, researchers at BWH will perform comprehensive routine protection, neurological, imaging, and PET studies on this patient. Normal investigations at the BWH will include the modification of immunological and neurodegenerative indicators.

    Previous record of Phase 1 Trial

    Tiziana previously completed a Phase 1 trial in healthy subjects with a single-site, double-blind, placebo-controlled, multiple ascending dose (MAD) one time in a day dosing for 5 days with nasally administered Foralumab. At doses up to 250 mg, the treatment was well received, with no drug-related adverse effects recorded. Professor Howard of BHW invented nasal foralumab.

    Also,

    TLSA had previously confirmed that the Clinical Trial of Nasal Administration with Foralumab in COVID-19 patients in Brazil had yielded promising results. Nasally administered Foralumab at 100 mg/day for a 10-day treatment period was found to be well-tolerated, with no serious adverse effects reported. Clinical evidence suggested that the procedure reduced lung inflammation significantly. This indicates that the recent development is expected to raise the progress graph for TLSA.

  • Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Seneca Biopharma Inc. (SNCA), a Biotechnology company, rose about 0.2% at $0.96 in pre-market trading Friday after declaring merger agreement with Leading BioSciences, Inc. under which a wholly owned subsidiary of Seneca will merge with LBS in an all-stock transaction.

    Palantir Technologies Inc. (PLTR) lost over -3.97% at $26.15 in pre-market trading Friday December 18, 2020 after reporting that it will hold its inaugural “Live Demo Day” on Tuesday, January 26, 2021 at 4:30pm ET.

    Atossa Therapeutics Inc. (ATOS) stock plunged -0.02% to $0.86 in the pre-market trading following its declaration of pricing of $14.0 million registered direct offering priced at-the-market. The most recent rating by Maxim Group, on January 26, 2018, is a Buy.

    Virgin Galactic Holdings Inc. (NYSE: SPCE) shares are trading down -6.27% at $23.9 at the time of writing. The company recently revealed an update following its test flight on December 12, 2020. Company’s 52-week ranged between $9.06 to $42.49. Analysts have a consensus price target of $19.

    BlackBerry Limited (BB), a Software – Infrastructure company, dropped about -4.36% at $7.9 in pre-market trading Friday after releasing its financial results for the three months ended November 30, 2020

    Before the trading started on December 18, 2020, Uxin Limited (UXIN) is up 4.5% to reach $1.16 following its announcement of unaudited financial results for the quarter ended September 30, 2020. It has been trading in a 52-week range of $0.72 to $3.07.

    Coeur Mining Inc. (CDE) stock plunged -2.98% to $10.76 in the pre-market trading. The firm recently revealed details of the expansion of its Rochester silver-gold mine in Nevada, reflecting significant reserve growth and the benefits of a larger-scale expansion project. The most recent rating by Noble Capital Markets, on September 14, 2020, is an Outperform.

    Novan Inc. (NASDAQ: NOVN) shares are trading up 6.25% at $0.68 at the time of writing. The company lately reported that it has enrolled 525 patients of the approximately 850 patients expected to enroll in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206. Company’s 52-week ranged between $0.22 to $3.72.

    CNS Pharmaceuticals Inc. (CNSP), a Biotechnology company, rose about 15.2% at $2.88 in pre-market trading Friday after announcing FDA approval of IND application for its brain cancer drug candidate Berubicin.

    United States Steel Corporation (X) stock moved down -4.26 percent to $17.77 in the pre-market trading after reporting that fourth quarter 2020 adjusted EBITDA is expected to be approximately $55 million and expected fourth quarter 2020 adjusted diluted loss per share to be approximately ($0.85).

    BioCardia Inc. (BCDA) lost over -6.09% at $4.01 in pre-market trading Friday December 18, 2020 following an announcement from the firm that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial.

    Before the trading started on December 18, 2020, Ampio Pharmaceuticals Inc. (AMPE) is up 8.43% to reach $1.93 after revealing the completion of its Phase I clinical trial and initiation of the first steps for a global Phase II clinical trial for intravenous (“IV”) Ampion treatment in COVID-19 patients. It has been trading in a 52-week range of $0.31 to $1.69.

    Drive Shack Inc. (NYSE: DS) shares are trading up 5.47% at $3.47 at the time of writing following the opening of its 65,000-square-foot entertainment golf venue located in Orlando. Company’s 52-week ranged between $0.86 to $4.19. Analysts have a consensus price target of $4.

    IZEA Worldwide Inc. (IZEA) tumbled over -3.7% at $1.04 in pre-market trading today. The company recently reported that it has just been awarded a mid-six figure contract from a Fortune 500 Manufacturer.

    Exela Technologies Inc. (XELA), a Software – Application company, rose about 81.87% at $0.66 in pre-market trading Friday after declaring that it has entered into a 5-year, $145 million term loan facility with Angelo Gordon, a global alternative investment firm.

    FedEx Corporation (FDX) stock moved down -2.89 percent to $283.8 in the pre-market trading after declaring strong results for the quarter ended November 30.

    Guardion Health Sciences Inc. (GHSI) stock plunged -2.13% to $0.23 in the pre-market trading. The firm recently declared progress on the introduction of its new vision support/energy drink, Epiq-V, which is under development for the United States and international markets.

    Amyris Inc. (NASDAQ: AMRS) shares are trading up 3.68% at $4.23 at the time of writing. Company’s 52-week ranged between $1.40 to $6.07. Analysts have a consensus price target of $3.35.

    Mereo BioPharma Group plc (MREO), a Biotechnology company, rose about 40.27% at $3.1 in pre-market trading Friday following the declaration of a license and collaboration agreement with Ultragenyx Pharmaceutical Inc. (RARE), for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI).

    Surface Oncology Inc. (SURF) gained over 17.51% at $10.0 in pre-market trading Friday December 18, 2020 after revealing exclusive license agreement with GSK for novel immunotherapy program.

    Neovasc Inc. (NVCN) is down more than -8.52% at $0.91 in pre-market hours Friday December 18, 2020 after reporting the publication of peer-reviewed article in EuroIntervention. The stock had jumped over 3.61% to $0.99 in the last trading session.

    BioLineRx Ltd. (BLRX) tumbled over -1.1% at $2.7 in pre-market trading today. The firm lately declared final results from Phase 2a COMBAT/KEYNOTE-202 triple combination study of Motixafortide in second line Metastatic Pancreatic Cancer (PDAC).

    VYNE Therapeutics Inc. (VYNE), a Biotechnology company, rose about 8.05% at $1.88 in pre-market trading Friday after declaring the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA).

    Before the trading started on December 18, 2020, Mesoblast Limited (MESO) is down -26.75% to reach $9.94 after announcing an update on COVID-19 ARDS trial. It has been trading in a 52-week range of $3.12 to $21.28.

    Applied DNA Sciences Inc. (APDN) stock plunged -12.02% to $5.49 in the pre-market trading after reporting consolidated financial results for the full fiscal year and quarter ended September 30, 2020. The most recent rating by H.C. Wainwright, on July 20, 2020, is a Buy.

    Conformis Inc. (NASDAQ: CFMS) shares are trading up 3.8% at $0.6693 at the time of writing. The firm lately revealed the U.S. commercial launch of the Company’s new Cordera™ Match Hip System. Company’s 52-week ranged between $0.50 to $1.66.

    Auris Medical Holding Ltd. (EARS) grew over 1.5% at $2.7 in pre-market trading today. The company recently provided a business update related to the Company’s funding position, its AM-301 program for the protection against airborne pathogens and allergens and the ongoing strategy review process.

    Sonoma Pharmaceuticals Inc. (SNOA) stock moved up 19.79 percent to $9.14 in the pre-market trading following the announcement of partnership with Gabriel Science, LLC for dental.

  • Stocks to Watch as Markets Look Set for a Calm, Boring Day

    Stocks to Watch as Markets Look Set for a Calm, Boring Day

    The markets are calm this morning, but they are largely positive. Investors are awaiting news from the ongoing Federal Reserve policy meeting. Part of the calm stems from the fact that the markets are not expecting much of a change from the Fed’s earlier stance on its inflation policy. Earlier, the Federal Reserve chairman Jerome Powell had stated that the Fed was implementing a new policy that it’s calling Average Inflation Targeting. Through this policy, the Federal Reserve is ready to allow prices to rise above the 2% target for some time, and use this to compensate for when inflation has to run below the targeted levels for extended periods. Since there are no expectations of a change from this stance from the current meeting, it has not created any kind of volatility in the markets. Nonetheless, the momentum is largely positive at the moment. The markets are still riding on the increased possibility of a COVID -19 vaccine coming out before the end of the year.  This would help drive up the economy to match the momentum that has been experienced in the equity markets over the last 5 months during the pandemic. Despite the relative calmness in the markets, there are stocks that are gaining faster than the overall market. Some of the best-performing stocks today ahead of markets opening are as below:

    Tiziana Life Sciences PLC [TLSA]

    Tiziana Life Sciences PLC is a top gainer this morning and is up by over 10% and gaining. This follows the company’s announcement that following a strategic review, it was demerging its StemPrintER and SPARE genomics business into a different listed company, called Accustem. The company stated the move would allow Accustem to commercialize the StemPrintER technology with cash of about a million pounds. It’s a move that unlocks value for the company’s shareholders.

    Eastman Kodak [NYSE: KODK]

    Eastman Kodak is another top gainer this morning and is up by over 50%. This follows the company’s announcement that it was actively addressing allegations that it had mishandled the stock option grants for its CEO just before it announced the loan awarded by the U.S government. The company has stated that it had agreed to act on a report on this process, and that includes a reorganization of the board.

    Myomo Inc [NYSE: MYO]

    Myomo Inc is a top performer this morning and is up by over 40%. This follows the company’s announcement that it had been certified as a Medicare provider. This will enable the company to bill Medicare directly when delivering its services in Washington DC, and in 39 States.